The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 23, 2018
Filed:
Jun. 07, 2016
Applicant:
Galderma Research & Development, Biot, FR;
Inventors:
Michael Graeber, Lawrenceville, NJ (US);
Janusz Czernielewski, Biot, FR;
Assignee:
GALDERMA RESEARCH & DEVELOPMENT, Biot, FR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/192 (2006.01); A61K 9/06 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/32 (2006.01); A61K 31/07 (2006.01); A61K 8/362 (2006.01); A61Q 17/04 (2006.01); A61K 8/368 (2006.01); A61Q 19/00 (2006.01); A61K 8/36 (2006.01); A61K 47/02 (2006.01); A61K 47/06 (2006.01); A61K 47/14 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); A61K 9/08 (2006.01); A61K 31/203 (2006.01); A61K 47/69 (2017.01);
U.S. Cl.
CPC ...
A61K 31/192 (2013.01); A61K 8/36 (2013.01); A61K 8/362 (2013.01); A61K 8/368 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 31/07 (2013.01); A61K 47/02 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61Q 17/04 (2013.01); A61Q 19/007 (2013.01); A61Q 19/008 (2013.01); A61K 31/203 (2013.01); A61K 47/6903 (2017.08); C07C 2103/74 (2013.01); C07C 2603/74 (2017.05); Y10S 514/859 (2013.01);
Abstract
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.